TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo December 27, 2021 Kobi Altman Chief Financial Officer ICL Group Ltd. Millennium Tower 23 Aranha Street P.O. Box 20245 Tel Aviv 61202 Israel Re: ICL Group Ltd. Form 20-F for the Fiscal Year Ended December 31, 2020 Filed March 2, 2021 File No. 001-13742 Dear Mr. Altman: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 20-F for the Fiscal Year Ended December 31, 2020 Note 8 - Investments in Subsidiaries A. Non-controlling interests in subsidiaries, page 40 1. We note the disclosure here and on page 127 that you hold a 50% interest in Yunnan Phosphate Haikou Co. Ltd. ("YPH") and refer to the entity as a joint venture. Given that you do not appear to hold a majority interest in YPH, please explain the nature and terms of the arrangement and your rights and obligations thereunder that provided you with a controlling interest in this entity. Describe your accounting for the arrangement under IFRS 10. Kobi Altman ICL Group Ltd. December 27, 2021 Page 2 In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Gary Newberry at (202) 551-3761 or Kevin J. Kuhar, Accounting Branch Chief, at (202) 551-3662 with any questions. FirstName LastNameKobi Altman Sincerely, Comapany NameICL Group Ltd. Division of Corporation Finance December 27, 2021 Page 2 Office of Life Sciences FirstName LastName